CD4 and tuberculosis: Between January and December 2023, participants of this cohort underwent a testing intervention that included VISITECT CD4 Advanced Disease (Accubio), CrAg LFA (IMMY), TB LAM Ag (Abbott) and Histoplasma urine antigen LFA test (MiraVista) testing.